The concept of immune response and its manifestations on medical imaging can have an impact on determining the course of treatment for the patient.
TORONTO (PRWEB) June 29, 2020
Join Julie Cole, M.D., VP, Medical Imaging, Oncology, Bioclinica, Rob Scarimbolo, Senior Director, Medical & Scientific Affairs, Bioclinica and Zachary LaVoie, Medical & Scientific Affairs Sr. Manager, Bioclinica in a live webinar on Thursday, July 16, 2020 at 11am EDT (4pm BST/UK).
As immunotherapies continue to evolve, the assessment of disease progression can be challenging to distinguish from the immune response. The concept of immune response and its manifestations on medical imaging can have an impact on determining the course of treatment for the patient.
The iRECIST criteria aims to reduce the ambiguity of this issue by implementing new evaluation methods for documenting and confirming disease progression. The goal of this webinar is to discuss an operational approach for using the iRECIST criteria in support of oncology clinical trials. The methodology for documenting various imaging data points including establishment and confirmation of progression will be elucidated.
For more information or to register for this event, visit iRECIST Criteria: An Operational Approach in Oncology Clinical Trials.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.